John Lewis of Hungerford
AVOIDKitchen designer and maker John Lewis of Hungerford’s second half financials may have shown improvement, but the outlook for the Oxfordshire-headquartered concern remains cloudy at best.
Overall, annual numbers to August from John Lewis, which sells its wares, including the ‘Artisan’ kitchen and furniture range, from its own showrooms as well as via company managed concessions, were poor, with pre-tax losses widening from £91,000 to £332,000.
In line with recession-hit kitchen industry competitors, John Lewis experienced a tough first half, typified by a disappointing winter selling season. However, as management had predicted, a better second half was had. And so whilst full year revenue reduced by 11% to £4.1m (2008: £4.6m), this was a lesser rate of decline than the 25% turnover retreat reported at the interim and second half sales were actually 2% up year-on-year at the best part of £2.5m.
Furthermore, this full year loss was better than the £509,000 deficit declared at the interim, reflecting the benefits of cost cutting, gross margin expansion and the £177,000 profit achieved in the second half. In another encouraging sign, John Lewis' year-end order book was 25% ahead of the previous year, reflecting a strong summer sale and ‘improving trends’ in consumer confidence. Drawing some confidence from its superior second half, John Lewis has since gone on to introduce new ranges into its showrooms and has even restarted its search for new showrooms.
Nevertheless, despite recent financial improvements, the outlook for consumer spending in 2010 is still highly uncertain and with almost £71,000 of cash having exited the business last year, this tiny retailer is best avoided for the time being.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £1.961m
PE Forecast: n/a
Share price: 1.05p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
